E2SSB 5981
SignedSenate
340B drug pricing program
Concerning the 340B drug pricing program.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill prevents drug manufacturers from limiting how Washington’s safety net health providers—like community health centers and tribal clinics—can get discounted medications through contract pharmacies. It aims to protect patient access to affordable drugs and ensure providers can use savings to support community health services. The law also gives providers and the state attorney general legal tools to enforce these protections.
- Prohibits drug manufacturers (and their distributors or third-party logistics providers) from blocking or restricting how 340B-covered safety net providers or their contracted pharmacies receive or dispense discounted 340B drugs.
- Bars manufacturers from requiring covered entities or pharmacies to share prescribing, purchasing, or other data as a condition for receiving discounted drugs—unless federal law requires it.
- Allows 340B-covered providers to sue manufacturers for violations and seek court orders (injunctions), civil penalties of up to $5,000 per package per violation, and reimbursement for legal costs.
- Authorizes the state attorney general to enforce the law under Washington’s Consumer Protection Act, treating manufacturer restrictions as unfair or deceptive business practices.
- Clarifies that the law does not override federal requirements—if federal law prohibits a practice, that federal rule still applies.
Who is affected
- Washington’s 340B-covered safety net providers — These include federally qualified health centers, Ryan White HIV clinics, tribal and urban Indian health centers, critical access hospitals, and other safety net hospitals that serve low-income and uninsured patients. They rely on savings from discounted drug prices to fund essential services like patient assistance, transportation, and community health programs.
- Vulnerable and underserved patients — Patients who rely on these providers for affordable medications and health services—especially low-income, uninsured, or underinsured individuals—may face reduced access to drugs or support services if manufacturers restrict 340B drug distribution.
- Contract pharmacies serving 340B providers — Pharmacies that contract with 340B providers to dispense discounted medications may be restricted by manufacturers from fulfilling prescriptions for eligible patients unless this law prevents such restrictions.
Pro/Con Analysis
Stronger case for concerns
Potential Concerns (5)
Prevents drug manufacturers from restricting how safety net providers and their contract pharmacies receive or dispense discounted 340B drugs, thereby preserving access to affordable medications for vulnerable patients.
HealthcarePeopleRef: Sec. 3(1)Bars manufacturers from requiring data sharing (e.g., prescribing, purchasing) as a condition for discounted drug access—protecting provider autonomy and reducing administrative burden on already-resourced-constrained clinics.
HealthcarePeopleRef: Sec. 3(2)Empowers covered entities to sue manufacturers for violations and recover civil penalties up to $5,000 per package, strengthening enforcement capacity and deterring manufacturer overreach.
HealthcarePeopleRef: Sec. 4(1)Authorizes the state attorney general to enforce the law under the Consumer Protection Act, treating manufacturer restrictions as unfair or deceptive practices—providing a powerful, state-backed enforcement mechanism.
HealthcarePeopleRef: Sec. 4(2)May reduce long-term public health costs by helping safety net providers maintain essential services (e.g., preventive care, chronic disease management), potentially decreasing reliance on emergency rooms and hospitalizations.
Public SafetyPeopleRef: Fiscal Impact
Who Is Most Affected
These providers rely on 340B savings to fund patient assistance, transportation, case management, and other non-reimbursed services. This bill directly protects their ability to access discounted drugs and reinvest savings, strengthening their operational sustainability.
Low-income, uninsured, and underinsured patients—especially those in rural or marginalized communities—benefit from preserved access to affordable medications and expanded support services funded by 340B savings. Restrictions could have directly reduced their access to care.
Contract pharmacies serving 340B providers will no longer be subject to manufacturer-imposed restrictions on dispensing discounted drugs, preserving their role in the care continuum and avoiding lost revenue or contractual penalties.
Large pharmaceutical manufacturers may face increased compliance costs, potential litigation exposure, and reduced ability to control distribution channels—though the bill does not ban discounts, only restrictive practices.
State and local governments benefit indirectly through reduced public health costs and stronger safety net infrastructure; however, the state incurs no direct fiscal cost and gains only potential civil penalties (which are unlikely to offset broader system savings).